MiNK Therapeutics, Inc. (INKT): Price and Financial Metrics
GET POWR RATINGS... FREE!
INKT Stock Price Chart Interactive Chart >
INKT Price/Volume Stats
| Current price | $2.24 | 52-week high | $4.32 |
| Prev. close | $2.21 | 52-week low | $1.09 |
| Day low | $2.21 | Volume | 8,150 |
| Day high | $2.34 | Avg. volume | 10,986 |
| 50-day MA | $2.43 | Dividend yield | N/A |
| 200-day MA | $2.07 | Market Cap | 75.68M |
MiNK Therapeutics, Inc. (INKT) Company Bio
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Latest INKT News From Around the Web
Below are the latest news stories about MINK THERAPEUTICS INC that investors may wish to consider to help them evaluate INKT as an investment opportunity.
MiNK Therapeutics to Participate in B. Riley Securities Oncology ConferenceNEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET. Access |
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call TranscriptMiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2022 Earnings Call Transcript November 6, 2022 Operator: Good morning, and welcome to MiNK Therapeutics’ Third Quarter 2022 Conference Call and Webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note, this event is being recorded. If anyone has any objections, you may disconnect at […] |
MiNK Therapeutics (INKT) Stock: Undervalued Given Platform''s PotentialMiNK Therapeutics reported positive results from two Phase 1 trials. Read why I think INKT stock is undervalued. |
MiNK Therapeutics to Participate in Evercore ISI HealthCONx ConferenceNEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 5 th Annual Evercore ISI HealthCONx Conference on Thursday December 1 st , at 4:45 PM ET. |
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From FridayGainers ShiftPixy, Inc. (NASDAQ: PIXY ) shares surged 56.6% to settle at $19.10 on Friday. Shares of several companies in the broader industrial space traded higher on continued hopes of softer Fed policy after CPI this week showed October inflation below estimates. Exela Technologies, Inc. (NASDAQ: XELA ) gained 50.3% to close at $0.2780. The company is expected to report Q3 results on November 14, 2022. uCloudlink Group Inc. (NASDAQ: UCL ) jumped 49.6% to close at $1.90. uCloudlink Group is expected to report Q3 financial results on November 16, 2022. Core Scientific, Inc. (NASDAQ: CORZ ) gained 44.3% to settle at $0.1981. Compass, Inc. (NYSE: COMP ) jumped 44% to close at $3.50. Compass posted a wider-than-expected loss for its third quarter, while sales topped estimates. Kaleyra, In... |
INKT Price Returns
| 1-mo | 2.75% |
| 3-mo | 10.34% |
| 6-mo | 70.99% |
| 1-year | -22.22% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -14.18% |
| 2022 | -41.48% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...